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Abstract: Mutations in the skeletal muscle-specific CLC-1 chloride channel are associated with the
human hereditary disease myotonia congenita. The molecular pathophysiology underlying some
of the disease-causing mutations can be ascribed to defective human CLC-1 protein biosynthesis.
CLC-1 protein folding is assisted by several molecular chaperones and co-chaperones, including
FK506-binding protein 8 (FKBP8). FKBP8 is generally considered an endoplasmic reticulum- and
mitochondrion-resident membrane protein, but is not thought to contribute to protein quality control
at the cell surface. Herein, we aim to test the hypothesis that FKBP8 may regulate CLC-1 protein
at the plasma membrane. Surface biotinylation and subcellular fractionation analyses reveal that a
portion of FKBP8 is present at the plasma membrane, and that co-expression with CLC-1 enhances
surface localization of FKBP8. Immunoblotting analyses of plasma membrane proteins purified from
skeletal muscle further confirm surface localization of FKBP8. Importantly, FKBP8 promotes CLC-1
protein stability at the plasma membrane. Together, our data underscore the importance of FKBP8 in
the peripheral quality control of CLC-1 channel.
Keywords: ion channels; molecular chaperones; membrane proteins; protein stability; trafficking;
skeletal muscle
1. Introduction
In skeletal muscles, up to 80% of the resting membrane conductance is determined by the
voltage-dependent CLC-1 chloride (Cl−) channel [1–3], indicating that the Cl− channel is essential
for setting the resting membrane potential after firing of action potentials. Mutations in the human
gene (CLCN1) encoding CLC-1 channels have been linked to the hereditary skeletal muscle disorder
myotonia congenita, which manifests delayed muscle relaxation following voluntary contraction [4–7].
Whereas many disease-associated mutations entail altered channel gating functions [8–11], some other
mutations lead to disruptive biosynthesis of CLC-1 channels [12–15].
The human CLC-1 mutant A531V, a myotonia congenita-causing mutation [16,17], is associated
with substantially reduced whole-cell current density that can be attributed to enhanced proteasomal
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and lysosomal degradations, as well as defective membrane trafficking [12,13]. Previous studies
from our lab further demonstrate that, at the endoplasmic reticulum (ER), CLC-1 protein is subject
to an ER-associated degradation mechanism mediated by the Cullin 4A/B E3 ubiquitin ligase
complex [18]. Moreover, the ER quality control system for CLC-1 protein involves the molecular
chaperones heat shock cognate protein 70 (Hsc70) and heat shock protein 90β (Hsp90β), as well as
the co-chaperones Hsp70/Hsp90 organizing protein (HOP), activator of Hsp90 ATPase homolog 1
(Aha1), and FK506-binding protein 8 (FKBP8; also known as FKBP38) [19], many of which have also
been shown to take part in ER quality control of other proteins such as cystic fibrosis transmembrane
conductance regulator (CFTR) Cl− channel and human ether-à-go-go-related gene potassium (K+)
channel [20–25]. Importantly, our data suggest that Hsp90β and FKBP8 may play a central role in
ER quality control of CLC-1 protein by dynamically coordinating with the Cullin 4A/B ubiquitin
ligase complex.
The nature of the molecules governing CLC-1 protein quality control at the plasma membrane,
however, remains elusive. Among the CLC-1-interacting ER molecular chaperones and co-chaperones
we identified, FKBP8 is unique in that it is a membrane-resident protein [26,27], and the co-chaperone
displays the most significant effect in enhancing CLC-1 protein expression at the plasma membrane [19].
This prominent increase in surface expression implies that, at the ER, FKBP8 is distinctively effective
in facilitating membrane trafficking of CLC-1 protein. Alternatively, the data can be interpreted as
that FKBP8 may play an active role in the protein quality control of CLC-1 at the plasma membrane,
thereby notably improving surface protein stability of the Cl− channel. Nonetheless, to date there
is no direct evidence supporting plasma membrane-localization of FKBP8. In this study, we aim to
address this critical issue by applying various biochemical approaches to investigate whether FKBP8
and CLC-1 may be co-localized at the plasma membrane. Overall, our results are consistent with the
idea that FKBP8 may directly contribute to the maintenance of CLC-1 protein quality at the cell surface.
2. Results
2.1. Surface Biotinylation of FKBP8
By performing co-immunoprecipitation and glutathione S-transferase (GST) pull-down assays,
we previously showed that FKBP8 is a binding partner of human CLC-1 channel [19]. Furthermore,
in line with our prior surface biotinylation studies, Figure 1A shows that co-expression with
Myc-tagged FKBP8 (Myc-FKBP8) promoted both total and surface expressions of Flag-tagged CLC-1
(Flag-CLC-1) in HEK293T cells. To address the possibility that FKBP8 may be present at the plasma
membrane, we began by investigating whether FKBP8 can be identified by surface biotinylation assay.
Surprisingly, a notable fraction of Myc-FKBP8 was indeed detected by surface biotinylation (Figure 1B,
left panel). Moreover, co-expression with Flag-CLC-1 resulted in about 3-fold increase in the surface
signal, but not the total protein level, of Myc-FKBP8 (Figure 1B), suggesting that the presence of CLC-1
may enhance cell surface level of FKBP8.
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Cell lysates from biotinylated intact cells were subject to either direct immunoblotting analyses (Total) 
or streptavidin pull-down prior to immunoblotting (Surface), using the indicated antibodies (α-Myc, 
α-Flag, or α-GAPDH). Total represents about 8% of the amount of the protein used for streptavidin 
pull-down. The molecular weight markers (in kDa) are labeled to the left. GAPDH expressions are 
shown as the loading control. (Right) Quantification of total and surface CLC-1 protein levels (n = 6). 
The protein density was normalized to that of the corresponding vector control; (B) Surface 
biotinylation analysis of Myc-FKBP8 in the absence or presence of Flag-CLC-1. (Left) Representative 
immunoblots. (Right) Quantification of FKBP8 protein levels and membrane trafficking (n = 8). The 
membrane trafficking efficiency of FKBP8 was expressed as surface protein density divided by the 
corresponding total protein density (Surface/total); (C) Representative immunoblots showing surface 
biotinylation analysis of Myc-Aha1, HA-HOP, HA-Hsp90β, or Myc-Hsc70, in the absence or presence 
of Flag-CLC-1. Asterisks denote significant difference from the control (*, t-test: p < 0.05). 
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Figure 1. Detection f cell surface FKBP8 express iotinylation. (A) Surface biotinylation
experim nts on HEK293T cells r ssing Flag-CLC-1 in th absenc or presence of Myc-FKBP8.
(Left) Representative i munoblots. Co-expression with the Myc vector was used as the vector control
(-). Cell lysates from biotinylated intact cells were subject to either direct immunoblotting analyses
(Total) or streptavidin pull-down prior to immunoblotting (Surface), using the indicated antibodies
(α-Myc, α-Flag, or α-GAPDH). Total represents about 8% of the amount of the protein used for
streptavidin pull-down. The molecular weight markers (in kDa) are labeled to the left. GAPDH
expressions are shown as the loading control. (Right) Quantification of total and surface CLC-1
protein levels (n = 6). The protein density was normalized to that of the corresponding vector control;
(B) Surface biotinylation analysis of Myc-FKBP8 in th abse ce or pres nce of Flag-CLC-1. (Left)
Repres ntative immunoblots. (Right) Quantific tion of FKBP8 p otein lev ls and membrane trafficking
(n = 8). The membrane trafficking efficiency of FKBP8 was expressed as surface protein density divided
by the corresponding total protein density (Surface/total); (C) Representative immunoblots showing
surface biotinylation analysis of Myc-Aha1, HA-HOP, HA-Hsp90β, or Myc-Hsc70, in the absence or
presence of Flag-CLC-1. Asterisks denote significant difference from the control (*, t-test: p < 0.05).
In addition to FKBP8, we have demonstrated that the ER quality control system for CLC-1 protein
also involves the co-chaperones and molecular chaperones Aha1, HOP, Hsp90β, and Hsc70 [19].
Interestingly, Hsp90 and Hsp70 were found to be present at the cell surface of some tumor cells and
developing neurons [28–31]. We therefore repeated the same biotinylation experiments with Aha1,
HOP, Hsp90β, and Hsc70 to explore their potential cell surface localization in our heterologous
expression system. Figure 1C clearly indicates tha , regardless of whe her CLC-1 was pr sent,
no discernible surface biotinylation sig al w s found for the ot er LC-1-interacting co-chaperones
and chaperones. This negative result, however, does not exclude the possibility that some of these
molecular chaperones and co-chaperones may be associated with CLC-1 at the plasma membrane.
2.2. Localization of FKBP8 at the Plasma Membrane a d the Golgi Complex by Subcellular Fractionation
In the following sets of experiments, we addressed the subcellular localization of FKBP8 and
CLC-1 by applying a variety of different fractionation analyses. We began by employing sucrose density
gradient centrifugation whereby lipid-soluble organelles were separated into 8 distinct fractions on
the basis their relative densities, with the density gradient increasing from fraction 1 toward fraction
8. Endogenous glyceraldehyde 3-phosphate dehydrogenase (GAPDH), calnexin, and cadherin in
Int. J. Mol. Sci. 2018, 19, 3783 4 of 19
HEK293T cells were used as the internal control for differentiating cytosolic, ER membrane, and plasma
membrane proteins, respectively. Calnexin is principally localized at two sub-domains of the ER,
the rough ER and the mitochondria-associated membrane [32–34], both of which are associated with
a higher density relative to the ER-Golgi intermediate compartment as well as the Golgi complex.
Given the fact that FKBP8 is typically considered as an internal membrane protein resident at the
ER and the mitochondria [26,35–37], it is likely that FKBP8 and calnexin share a similar localization
pattern within the ER.
Figure 2A shows that GAPDH was virtually undetectable at any of the 8 fractions, and that
calnexin was preferentially localized at the densest fraction 8. By contrast, cadherin was detected
mainly at fractions 2–4. Similar to the distribution pattern of cadherin, over-expressed Flag-CLC-1 was
identified at fractions 3–5; nonetheless, Flag-CLC-1 also displayed a significant localization at fractions
7–8. Therefore, these observations indicate that, in our sucrose gradient separation system, fraction 8
most likely corresponds to ER-resident membrane proteins, whereas fractions 3–4 comprise mainly
plasma membrane-resident proteins. To quantitatively evaluate the relative propensity for plasma
membrane localization of these proteins, we then calculated the ratio of protein signal intensities at
fractions 3 and 4 to those at fraction 8 [F(3+4)/F8]. As outlined in Figure 2B, the mean F(3+4)/F8 ratios
for calnexin, Flag-CLC-1, and cadherin were about 0.03, 1.87, and 6.87, respectively. The substantial
difference between the F(3+4)/F8 ratios of Flag-CLC-1 and cadherin is consistent with the common
notion that, compared to their endogenous counterparts, over-expressed plasma membrane proteins
are associated with a higher degree of ER retention. Moreover, upon co-expression with Myc-FKBP8,
Flag-CLC-1 exhibited concurrent reduced ER localization and enhanced plasma membrane localization
(Figure 2A), leading to about a 56% increase in the mean F(3+4)/F8 ratio (~2.92) (Figure 2B). By contrast,
no discernible change was found for the F(3+4)/F8 ratios of cadherin and calnexin (Figure 2B).
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panels) Densitometric quantification of the relative distribution (with respect to the total signal) in 
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2C; see also Figure 2B), leading to about a 4-fold increase in the mean F(3+4)/F8 value (~1.35) (Figure 
Figure 2. Sucrose gradient fractionation analyses of FKBP8 localization. Cell homogenates from
HEK293T cells transfected with the indicated cDNA constructs were analyzed by sucrose density
gradient centrifugation. Total homogenates (Total) were ultracentrifuged and separated into the
supernatant (Cytosol) and the membrane pellet (Memb) fractions. The membrane pellet fraction
was further sedimented through a discontinuous sucrose gradient and subsequently divided into
8 fractions, with the density gradient increasing from fraction 1 toward fraction 8. Specific markers
for distinct subcellular co partments were chosen by studying 3 endogenous proteins in HEK293T
cells: cadherin (plasma m mbrane protein), caln xi (ER-reside t membrane-associated protein),
and GAPDH (cytosolic protein). (A) (Left panels) Representativ immunoblots showing the subcellular
fractionation pattern of Flag-CLC-1 in the absence or p esence of Myc-FKBP8 co-expression. (Right
panels) Densitometric quantification of the relative distribution (with respect to the total signal) in
different fractions for each membrane-associated protein analyzed on the corresponding gel to the left;
(B) Statistical analyses of the ratio of protein signal intensities at fractions 3 and 4 to those at fraction 8
[F(3+4)/F8] for the indicated membrane-associated proteins in the absence or presence of Myc-FKBP8
(n = 3); (C) Representative sucrose gradient fractionation pattern of Myc-FKBP8 in the absence or
presence of Flag-CLC-1 co-expression; (D) Statistical analyses of the F(3+4)/F8 ratio for the indicated
membrane-associated proteins in the absence or presence of Flag-CLC-1 (n = 4). The asterisk denotes a
significant difference from the control (*, t-test: p < 0.05).
Next, we characterized the subcellular localization of Myc-FKBP8 with sucrose density gradient
centrifugation. As depicted in Figure 2C, in the absence of CLC-1, the strongest Myc-FKBP8 signal
was detected at fraction 8. Unlike the fractionation pattern of the ER- esident pr tein cal exin,
however, weak Myc-FKBP8 signals were also found at fractions 3–4 (Figure 2C). Indeed, the mean
F(3+4)/F8 ratio of Myc-FKBP8 was about 0.34, which is substantially larger than that of calnexin
(~0.03), albeit much smaller than that of cadherin (~7.21) (Figure 2D). Importantly, in the presence of
Flag-CLC-1 co-expression, Myc-FKBP8 signals were remarkably enhanced at fractions 3–4 (Figure 2C;
see also Figure 2B), leading to about a 4-fold increase in the mean F(3+4)/F8 value (~1.35) (Figure 2D).
By contrast, no measurable difference was detected for the F(3+4)/F8 ratios of cadherin and calnexin
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(Figure 2D). Together, the preceding sucrose gradient centrifugation results are consistent with the
idea that a small but significant fraction of over-expressed FKBP8 is localized at the plasma membrane,
and that CLC-1 may induce a redistribution of ER-resident FKBP8 to the plasma membrane.
If FKBP8 can indeed traffic from the ER to the plasma membrane, then a portion of the
co-chaperone should also be present at the Golgi complex. Although the Golgi complex is associated
with a lower density relative to the ER and the plasma membrane, it is not feasible to distinguish
protein distribution between the ER and the Golgi complex using standard sucrose gradient
fractionation [32,33]. Instead, differential centrifugation, a fractionation analysis based on different
sedimentation rates in response to increasing centrifugal force cycles (e.g., from 1000 to 100,000× g),
has been commonly applied to differentiate the localization of ER, plasma, and Golgi membrane
proteins [38,39]. For instance, compared to their Golgi counterpart, a significantly higher fraction of ER
membrane proteins is found in the pellets of 1000 to 15,000× g centrifugation forces [38,39]. Therefore,
we went on to perform differential centrifugation whereby cell homogenates were separated into 4
fractions by different centrifugal force cycles. Figure 3A exemplifies differential centrifugation analyses
of lysates from HEK293T cells over-expressing GFP-tagged trans-Golgi network 38 (GFP-TGN38),
a resident integral membrane proteins of the trans-Golgi network [40]. In agreement with the
high-sedimentation rate of ER, calnexin was retrieved from the pellets of 1000× g (1 k) and 10,000×
g (10 k), but virtually not from those of 100,000× g (100 k), centrifugation forces. The plasma
membrane protein cadherin was present in the pellets of 1 k, 10 k, and 100 k centrifugation forces,
with the strongest signal detected at the 10 k fraction. In comparison, Na+-K+-ATPase, another
endogenous plasma membrane protein in HEK293T cells, displayed a more comparable distribution
between 10 k and 100 k fractions, along with a minimal presence at the 1 k. Endogenous GM130,
a peripheral membrane protein at the cis-Golgi network [41], was also found at all three pellet
fractions, whereas the trans-Golgi-localized GFP-TGN38 was preferentially harvested from the 100 k
pellet. By contrast, the cytosolic protein GAPDH remained in the supernatant of 100 k centrifugation
force. To quantitatively compare the relative propensity for Golgi localization of these proteins, we then
calculated the ratio of protein signal intensity at the 100 k fraction to that at the 1 k fraction [100 k/1 k]:
the Golgi proteins GFP-TGN38 and GM130 were associated the highest mean 100 k/1 k ratios (~8.11
and 2.21, respectively), while Na+-K+-ATPase and cadherin showing intermediate values (~1.83 and
0.64, respectively), and calnexin the lowest (~0.01) (Figure 3A).
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Lik cadherin, Flag-CLC-1 was detected in the pellets of all three centrifugation forces, with the
10 k fraction showing the strongest signal (Figure 3B). In the presence of Myc-FKBP8 co-expression,
there was a notable reduction of Flag-CLC-1 signal at the 1 k fraction, as well as a parallel enhancement
at the 100 k fraction (Figure 3B), resulting in more than a 2-fold increase in the mean 100 k/1 k ratio,
from about 0.77 to about 1.60 (Figure 3C). In comparison, no measurable effect was found on the mean
100 k/1 k ratios of cadherin, calnexin, and GM130 (Figure 3C). These observations are consistent with
the notion that FKBP8 facilitates ER-exiting of the CLC-1 channel.
In direct contrast to the absence of calnexin in the 100 k pellet, Myc-FKBP8 was present in the
pellets of all three centrifugation forces (Figure 3D), leading to a mean 100 k/1 k ratio from about 0.46
(Figure 3E), which is more than 20-fold higher than that of calnexin (~0.02) (Figure 3E). Importantly,
co-expression with Myc-CLC-1 further increased the mean 100 k/1 k ratio of Myc-FKBP8 by almost
2-fold to about 0.88, with no discernible effect on that of cadherin, calnexin, or GM130 (Figure 3E).
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The foregoing data provide another line of evidence supporting the idea that a fraction of FKBP8 may
be president at the Golgi complex, and that over-expressing CLC-1 promotes ER-to-Golgi transition
of FKBP8.
All the preceding localization experiments involve over-expressed Myc-FKBP8 instead of
endogenous FKBP8, raising the concern that our conclusions may be based on artifacts instigated by
protein over-expression. To address this critical issue, we first examined the subcellular localization of
endogenous FKBP8 in HEK293T cells. Figure 4A illustrates that a significant fraction of endogenous
FKBP8 in HEK293T cells was indeed detected by surface biotinylation, and that over-expression of
Flag-CLC-1 led to about a 2-fold increase in the surface localization of endogenous FKBP8. By contrast,
regardless of whether Flag-CLC-1 was over-expressed in HEK293T cells, the endogenous ER-membrane
protein calnexin was not discernibly detected by surface biotinylation (Figure 4B). Furthermore, sucrose
density gradient analyses in Figure 4C demonstrate that a faint signal of endogenous FKBP8 was
present at fraction 3, with a mean F(3+4)/F8 ratio of about 0.15 (Figure 4D), which is significantly higher
than that of calnexin (~0.02) (Figure 4D), but lower than that of over-expressed Myc-FKBP8 (~0.34)
(Figure 2D). Importantly, Flag-CLC-1 co-expression induced a substantial increase of endogenous
FKBP8 signal at fraction 3 (Figure 4C), resulting in more than 2-fold increase in the mean F(3+4)/F8
ratio to about 0.4 (Figure 4D). In addition, differential centrifugation analyses detected considerable
FKBP8 signal in the 100 k pellet (Figure 4E). The estimated mean 100 k/1 k ratio of endogenous FKBP8
was about 0.25 (Figure 4F), which is lower than that of Myc-FKBP8 (~0.46) (Figure 3E), but distinctly
higher than that of calnexin (~0.02) (Figure 4F). Notably, Flag-CLC-1 co-expression also promoted
100 k-localization of endogenous FKBP8 (Figure 4E), leading to more than a 4-fold increase of the
mean 100 k/1 k ratio to about 1.01 (Figure 4F), which is comparable to that of Myc-FKBP8 (~0.88)
under the same co-expression condition (Figure 3E). Taken together, we infer that, in addition to
its known ER localization, endogenous FKBP8 in HEK293T cells is also resident at both the plasma
membrane and the Golgi complex. Significantly, like Myc-FKBP8, both plasma membrane- and Golgi
complex-localizations of endogenous FKBP8 are remarkably enhanced in the presence of the substrate
protein CLC-1.
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Figure 4. Subcellular localization of endogenous FKBP8 in HEK293T cells. (A) Surface biotinylation
analysis of endogenous FKBP8 in the absence or presence of Flag-CLC-1 over-expression (n = 3);
(B) Representative biotinylation result of endogenous calnexin in the absence or presence of
Flag-CLC-1 over-expression; (C) R presentative suc os density radient ce trifugatio pattern
of endogenous FKBP8 in HEK293T cells in the absence (Flag-vector) or presence (Flag-CLC-1)
of Flag-CLC-1 over-expressio ; (D) Statistical analyses of the F(3+4)/F8 ratio for the indicated
membrane-associated proteins in the absence or presence of Flag-CLC-1 (n = 4); (E) Representative
differential centrifugation pattern of endogenous FKBP8 in HEK293T cells in the absence or presence
of Flag-CLC-1 over-expression; (F) Statistical analyses of the 100 k/1 k ratio for the indicated
membrane-associated proteins in the absence or presence of Flag-CLC-1 (n = 4). The asterisk denotes a
significant difference from the control (*, t-test: p < 0.05).
In light of the fact that CLC-1 is a skeletal muscle-specific ion channel, we went on to investigate
whether endogenous FKBP8 in rat skeletal muscle may also be present at the plasma membrane.
Consistent with t presence of a 10-amino acid difference in protein size between the two FKBP8
homologu s, the apparent molecular weight of rat FKBP8 was relatively lower than th t of it human
counterpart (Figu e 5A). Figure 5B depicts a representative sucr se density gradient analysis of
endogenous proteins in rat skeletal muscle. As expected, endogenous CLC-1 and cadherin were
detected at fractions 3–5 and 2–4, respectively. However, in direct contrast to its virtually exclusive
localization at fraction 8 in HEK293T cells, endogenous calnexin in skeletal muscle was present at
the fractions 2–6, with a minimal signal at fraction 8. A similar widespread distribution pattern
in skeletal muscle was also found for endogenous FKBP8. The presence of this overlap between
ER and plasma membrane proteins in sucrose density gradient may be ascribed to the structural
complexity of ER (sarcoplasmic reticulum, SR) in skeletal muscle. The SR in skeletal muscle comprises
two domains interconnected in a network-like manner: the “light” longitudinal SR and the “heavy”
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junctional SR, with the latter being associated with the plasma membrane (sarcolemma and transverse
tubule) [42]. Moreover, calnexin and BiP, two of the most common ER-resident proteins, were found
to be widely distributed within both longitudinal and junctional SR [43]. In agreement with these
notions, sucrose density gradient per se does not appear to be effective in separating SR and plasma
membranes in skeletal muscle; rather, additional affinity purification procedures are required to
isolate the plasma membrane fraction [44]. We therefore chose an aqueous two-phase partition system
to isolate the plasma membrane of rat skeletal muscle [45,46]. Figure 5C demonstrates that both
endogenous CLC-1 and cadherin were readily detected at the surface membrane fraction. Most
importantly, endogenous FKBP8, but not calnexin, was present at the plasma membrane of skeletal
muscle. In addition, co-immunoprecipitation analyses confirmed the interaction of endogenous FKBP8
and CLC-1 in skeletal muscle (Figure 5D,E).
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assessed the significance of this co-localization on protein stability of surface CLC-1. By applying the 
protein translation inhibitor cycloheximide, we have previously shown that FKBP8 over-expression 
Figure 5. Plasma membrane-loc li ogenous FKBP8 in sk letal muscle. (A) Representative
protein signals of endogenous F i ( E 293T) cells (open triangle) and rat skeletal muscle
(filled triangle); (B) Representative sucrose fractionation pattern of endogenous FKBP8, CLC-1, cadherin,
calnexin, and GAPDH in rat skeletal muscle; (C) Representative immunoblot showing the presence of
rat muscle CLC-1, cadherin, and FBKP8 at the plasma membrane. Plasma membrane fraction (PM)
was isolated with an aqueous two-phase system. Note that GAPDH and calnexin are found in the total
protein fraction (Total), but not in the plasma membrane fraction; (D,E) Co-immunoprecipitation of
FKBP8 and CLC-1 in skeletal muscle. Muscle lysates were subject to immunoprecipitation (IP) with the
anti-CLC-1 (D) or anti-FKBP8 (E) antibody, followed by immunoblotting with the indicated antibodies.
Rabbit IgG was employed to verify the specificity of immunoprecipitation. Corresponding expression
levels of CLC-1 and FKBP8 in the lysates are shown in the Input lane. Input represents about 10% of
the total protein used for immunoprecipitation. h.c.: IgG heavy chain.
2.3. Regulation of Surface CLC-1 Stability by FKBP8
Having established the co-localization of FKBP8 and CLC-1 at the plasma membrane, we then
assessed the significance of this co-localization on protein stability of surface CLC-1. By applying the
protein translation inhibitor cycloheximide, we have previously shown that FKBP8 over-expression
prolonged the half-life of total CLC-1 protein by more than 50% [19]. One plausible approach to
evaluating protein half-life of surface CLC-1 would involve performing cycloheximide chase analyses
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of surface biotinylated CLC-1 signal. Nonetheless, given that FKBP8 is known to promote membrane
trafficking of CLC-1 [19], the cycloheximide chase experiment does not appear to be appropriate for
assessing the effect of the co-chaperone on surface CLC-1 stability. Instead, we employed brefeldin
A (BFA), which inhibits forward trafficking of proteins from the ER to the Golgi [47], to investigate
the effect of FKBP8 co-expression on protein stability of plasma membrane-resident CLC-1. In other
words, as a result of BFA-induced blockade of forward trafficking, the time course of the reduction
in surface biotinylated CLC-1 protein in response to increasing BFA treatment durations reflects the
turnover rate of CLC-1 channels at the plasma membrane, a quantitative analysis known as BFA chase
assay [48]. Figure 6 exemplifies the BFA chase response of surface CLC-1 protein: in the presence
of FKBP8, the estimated protein half-life of surface CLC-1 dramatically increased from about 8.4 to
about 14.8 h, implying that FKBP8 may effectively enhance protein stability of CLC-1 at the plasma
membrane. Consistent with this notion, our previous functional analyses using patch clamp recording
demonstrated that co-expression with FKBP8 substantially enhanced CLC-1 current level [19].
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3. Discussion
FKBP8, a member of the FK506-binding protein family, is a membrane-anchored immunophilin
that serves as a potential peptidyl-prolyl cis-trans isomerase in the ER quality control
system [21,22,24,27,49,50]. Traditionally, FKBP8 is regarded as an internal membrane protein resident
at the ER and the mitochondria [26,35–37]. In the current study, we employed various biochemical
techniques to provide the novel evidence indicating that FKBP8 may also be localized at the Golgi
complex and the plasma membrane. Nevertheless, based on the mean F(3+4)/F8 ratios derived from
our sucrose density gradient analyses, FKBP8 (~0.12–0.34) does display a markedly reduced propensity
for cell surface localization, as compared to typical plasma membrane proteins such as cadherin
(~6.31–9.02), CLC-1 (~1.87–2.92), and KV1.1 (~0.66–1.23).
We previously demonstrated that the molecular chaperones Hsc70 and Hsp90β, as well as the
co-chaperones HOP, Aha1, and FKBP8, are binding partners of human CLC-1 channel [19]. In the ER
quality control system of CLC-1 protein, Hsc70 and HOP appear to mediate a facilitating process at an
early stage, followed by a Hsp90β cycle that entails a concerted work by Aha1, Hsp90β, and FKBP8 to
further promote CLC-1 folding [19]. Hsp90β and FKBP8 may additionally contribute to ER-associated
degradation of misfolded CLC-1 by interacting with the Cullin 4A/B E3 ubiquitin ligase. Importantly,
compared to the other molecular chaperones and co-chaperones, FKBP8 displays a profoundly
significant effect in increasing membrane expression of CLC-1 protein. This prominent increase
in surface expression clearly highlights the notion that FKBP8 is distinctively effective in assisting
ER exiting of CLC-1. In the present study, we further demonstrated that FKBP8 may be co-localized
with CLC-1 at both the Golgi complex and the plasma membrane. Interestingly, co-expression with
the substrate protein CLC-1 results in enhanced Golgi- and plasma membrane-localization of FKBP8.
Taken together, we propose that, in addition to serving as an ER-resident co-chaperone, FKBP8
may usher the membrane trafficking process of CLC-1 from the ER, through the Golgi complex,
and eventually to the plasma membrane. Remarkably, our data also indicate that FKBP8 effectively
prolongs CLC-1 protein half-life at the cell surface. Consequently, the FKBP8-induced increase
in surface expression may in part be accounted for by enhanced CLC-1 protein stability at the
plasma membrane.
Emerging evidence supports the notion that membrane proteins are subject to peripheral
quality control whereby protein homeostasis at the cell surface is stringently controlled by protein
conformation surveillance and endosomal-lysosomal degradation systems [51–53]. Disruption in
protein stability at the plasma membrane has been implicated in many human diseases. For example,
CFTR ∆F508, the most common cystic fibrosis-causing mutation [54,55], is associated with enhanced
lysosomal degradation [56,57]. A similar defect in surface stability has also been demonstrated for
the myotonia congenita-causing CLC-1 A531V mutation [13]. Despite its well documented function
in ER quality control [20–22], FKBP8 does not seem to contribute to the peripheral quality control of
CFTR [56]. In this report, we observed enhanced surface CLC-1 stability in the presence of FKBP8
over-expression. Hence, to the best of our knowledge, we provide the first direct evidence suggesting
that FKBP8 may play an essential role in the peripheral quality control of membrane protein.
Although we failed to detect CLC-1-induced surface biotinylation signals of Aha1, HOP,
Hsp90β, and Hsc70, we cannot discount the possibility that some of these molecular chaperones
and co-chaperones may still contribute to CLC-1 peripheral quality control, as has been suggested
for CFTR [56]. Further investigation is required to understand how FKBP8 interacts with
chaperones/co-chaperones, as well as counteracting E3 ubiquitin ligases, to maintain CLC-1 protein
homeostasis at the plasma membrane. It is also important in the future to ascertain how FKBP8 assists
CLC-1 trafficking in post-ER compartments. In addition, ER-related chaperones and co-chaperones
are required for the assembly of ion channel subunits [58,59]. Hence it will be interesting to address
whether FKBP8 may facilitate the dimerization of CLC-1 subunits at the ER.
Defective protein stability in CLC-1 channel has been associated with the loss-of-function
neuromuscular diseases myotonia congenita [12,13]. Emerging therapeutic strategies for human
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diseases focus on the identification of novel chemical interventions effective in adjusting anomalous
protein biosynthesis networks to restore normal physiology [60,61]. For myotonia congenita,
therefore, elucidation of the molecular mechanisms governing ER and peripheral quality control
systems is imperative for developing new approaches for correcting misfolded channel proteins.
Our demonstration of the important role of FKBP8 in peripheral quality control may shed light on the
search for pharmacological agents potentially effective in overcoming excessive clearance of the CLC-1
channel at the plasma membrane.
4. Materials and Methods
4.1. cDNA Constructs
Flag-CLC-1 was generated by subcloning human CLC-1 into the pFlag-CMV2 vector
(Sigma-Aldrich, St. Louis, MO, USA) [18]. Myc-FKBP8 was created by swapping mouse FKBP8
into the pcDNA3.1-Myc vector (Sigma-Aldrich) [19]. Additional cDNA constructs employed in this
study are pcDNA3.1-Myc mouse Aha1, pcDNA3-HA rat HOP, pcDNA5-V5 human Hsc70 (Addgene
19514, Watertown, MA, USA), pcDNA3-HA human Hsp90β (Addgene 22847), and pEGFP-rat TGN38
(kindly provided by Dr. Fan-Jen Lee, National Taiwan University, Taipei, Taiwan).
4.2. Cell Culture and DNA Transfection
Human embryonic kidney (HEK) 293T cells were grown in Dulbecco’s modified Eagle’s medium
(DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat-inactivated fetal bovine serum
(Hyclone, Logan, UT, USA), 2 mM glutamine, 100 units/mL penicillin, and 50 µg/mL streptomycin,
and were maintained at 37 ◦C in a humidified incubator with 95% air and 5% CO2. Transient
transfection was performed with the calcium phosphate method [62]. Cells were plated onto 12-well
plates or 10-cm dishes (for biochemical experiments), or poly-D-lysine-coated coverslips in 24-well
plates (for immunofluorescence experiments) 24 hrs before transfection. The amount of cDNA used
in each well was about 200 (for expression) to 500 (for immunoprecipitation) ng/mL. The molar
ratio for co-transfection was 1:1. After 6-hr incubation at 37 ◦C, the medium was changed and the
culture cells were maintained in the 37 ◦C incubator for 24–48 hrs before being used for biochemical or
immunofluorescence experiments. Where indicated, brefeldin A (Sigma-Aldrich) was added to the
culture medium.
4.3. Immunoblotting
Cells were washed twice with ice-cold phosphate buffered saline (PBS) [(in mM) 137 NaCl, 2.7 KCl,
4.3 Na2HPO4·2H2O, 1.4 KH2PO4, pH 7.3] supplemented with 2 mM EDTA, and re-suspended in a
lysis buffer [(in mM) 150 NaCl, 5 EDTA, 50 Tris-HCl pH7.6, 1% Triton X-100) containing protease
inhibitor cocktail (Roche Applied Science, Mannhaim, Germany). The Laemmli sample buffer was
added to the lysates, which in turn were sonicated on ice (3 times for 5 sec each) and heated at 70 ◦C
for 5 min. Samples were then separated by 7.5–10% SDS-PAGE, electrophoretically transferred to
nitrocellulose membranes, and detected using rabbit anti-Aha1 (1:2500; Thermo Scientific, Waltham,
MA, USA), mouse anti-cadherin (1:1000; Abcam, Cambridge, MA, USA), mouse anti-calnexin (1:1000;
Santa Cruz Biotechnology, Dallas, TX, USA), rabbit anti-CLC-1 (1:1000; Alomone, Jerusalem, Israel),
rabbit anti-Flag (1:5000; Sigma-Aldrich), rabbit anti-FKBP8 (1:5000; GeneTex, Hsinchu, Taiwan), rabbit
anti-GAPDH (1:8000; GeneTex), rat anti-HA (1:5000; Roche Applied Science), rabbit anti-GFP (1:5000;
Abcam), mouse anti-GM130 (1:1000; BD Biosciences, San Jose, CA, USA), rabbit anti-HOP (1:10,000;
Abcam), rabbit anti-Hsc70 (1:750; Abcam), rabbit anti- Hsp90β (1:500; Abcam), mouse anti-Myc (clone
9E10), or mouse anti-Na+-K+-ATPase (1:1000; Thermo Scientific) antibodies. Blots were exposed
to horseradish peroxidase-conjugated anti-mouse/rabbit IgG (1:5000; Jackson ImmunoResearch,
West Grove, PA, USA) or goat anti-rat IgG (1:5000; Santa Cruz Biotechnology), and then revealed by an
enhanced chemiluminescence detection system (Thermo Scientific). Results shown are representative
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of at least 3 independent experiments. Densitometric scans of immunoblots were quantified by using
ImageJ (National Institute of Health, Bethesda, MD, USA).
4.4. Cell Surface Biotinylation
Cells were rinsed with ice-cold Dulbecco’s phosphate buffered saline (D-PBS) (Sigma-Aldrich)
supplemented with 0.5 mM CaCl2, 2 mM MgCl2, incubated in 1 mg/mL sulfo-NHS-LC-biotin (Thermo
Scientific) in D-PBS at 4 ◦C for 1 hr with gentle rocking on an orbital shaker, and subject to a quenching
procedure by removing the biotin reagents and rinsing 3 times with 100 mM glycine in PBS, followed
by once in Tris buffered saline (TBS) [(in mM) 20 Tris-HCl, 150 NaCl, pH 7.4]. Cells were solubilized in
ice-cold lysis buffer [(in mM) 150 NaCl, 50 Tris-HCl, 1% Triton X-100, 5 EDTA, 1 phenylmethylsulfonyl
fluoride (PMSF), pH 7.6] supplemented with the protease inhibitor cocktail. Insolubilized materials
were removed by centrifugation at 4 ◦C. Solubilized cell lysates were incubated overnight at 4 ◦C with
streptavidin-agarose beads (Thermo Scientific). Beads were washed once in the lysis buffer, followed
by twice in a high-salt buffer [(in mM) 500 NaCl, 5 EDTA, 50 Tris-HCl, pH7.6, 0.1% Triton X-100] and
once in a low-salt buffer [(in mM) 2 EDTA, 10 Tris-HCl, pH7.6, 0.1% Triton X-100]. Biotin-streptavidin
complexes were eluted from the beads by heating at 70 ◦C for 5 min in the Laemmli sample buffer.
For quantitative analyses, cell lysates from biotinylated intact cells were subject to either
direct immunoblotting analyses (Total) or streptavidin pull-down prior to immunoblotting (Surface).
Specifically, during sample loading for SDS-PAGE, the amount of lysates loaded in the Total lane
represents about 8% of that used for streptavidin pull-down and thereafter loading in the Surface lane.
For both Total and Surface signals, the protein density was standardized as the ratio to the cognate
total GAPDH signal. The membrane trafficking efficiency (Surface/total) was determined as the ratio of
surface protein density to the corresponding total protein density. In all cases, the mean value was
normalized to that of the corresponding vector control.
4.5. Subcellular Fractionation Analyses
Subcellular fractionation protocols were modified from our previously published procedures [48].
In general, cells were washed with ice-cold PBS, detached from dishes with pre-cooled PBS containing
2 mM EDTA, and pelleted for 5 min at 1000× g. Cell pellets were suspended in hypotonic buffer
(as specified below) and homogenized by 20 strokes in a Dounce homogenizer, followed by specific
processes for either sucrose fractionation or differential centrifugation.
For sucrose gradient fractionation, the hypotonic buffer comprises (in mM) 2 EDTA, 2 EGTA,
6 MgCl2, 20 HEPES, pH 7.4, and 1 PMSF, supplemented with protease inhibitor cocktail. Cell lysates
were further homogenized by stroking in a 23 G needle for 10 times, and then centrifuged at 1000× g
at 4 ◦C for 5 min to remove undisrupted cells. A portion of the supernatant was collected as the “total
homogenate”, and the rest was subject to 100,000× g centrifugation for 90 min, thereby separating
into the “cytosol” (supernatant) and the “membrane” (pellet) fractions. Pellets were rinsed with
and sonicated in hypotonic buffer, followed by suspension in hypotonic buffer supplemented with
2 M sucrose to achieve a 0.2 M final sucrose concentration. Membrane lysates were then loaded
on the top of a discontinuous sucrose gradient [2 M (0.4 mL), 1.5 M (0.75 mL), 1.35 M (0.75 mL),
1.2 M (0.75 mL), 0.9 M (0.5 mL), and 0.5 M (0.5 mL) in hypotonic buffer], and subject to a 32,000× g
centrifugation for 16 hr. Fractions were collected from the top of the gradient, including one 1-mL and
seven 0.5-mL fractions.
For differential centrifugation, the hypotonic buffer comprises (in mM) 20 Tris-HCl, 2 DTT,
10 EDTA, pH 7.9, and 1 PMSF supplemented with protease inhibitor cocktail. Cell lysates were
further homogenized by stroking in a 26 G needle for 10 times, re-suspended in 0.2 M sucrose in
hypotonic solution, and then centrifuged at 100× g at 4 ◦C for 10 min to remove undisrupted cells.
A fraction of the supernatant was collected as the “total homogenate”, and the rest was subject to
1000× g centrifugation for 10 min, generating the “1 k” pellet. The supernatant was then centrifuged
at 10,000× g for 30 min, generating the “10 k” pellet. The supernatant was further centrifuged at
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100,000× g for 90 min, generating the “100 k” pellet. The 1/10/100 k pellet was rinsed with hypotonic
buffer, followed by suspension and sonication in ice-cold lysis buffer [(in mM) 100 NaCl, 4 KCl,
2.5 EDTA, 20 NaHCO3, 20 Tris-HCl, pH 7.5, 1 PMSF] with 1% Triton X-100.
4.6. Isolation of Plasma Membrane Proteins from Rat Skeletal Muscle
Animals were anesthetized and sacrificed in accordance with the Guidelines for the Care and
Use of Mammals in Neuroscience and Behavioral Research (National Research Council 2003), as well
as following procedures approved by the Institutional Animal Care and Use Committee (IACUC) of
College of Medicine, National Taiwan University. Vastus lateralis muscle fibers were dissected from
adult Wistar rats as described previously [18]. Aqueous two-phase purification of plasma membrane
was accomplished by using the Plasma Membrane Protein Extraction Kit (Abcam). Briefly, muscle
tissues were homogenized using the hypotonic buffer for sucrose fractionation (0.05 g muscle in
2 mL buffer). Muscle lysates were further treated with the Homogenize Buffer Mix, followed by
micro-centrifugation at 1000× g and then 100,000× g at 4 ◦C for 5 and 90 min, respectively. The pellet,
which contains total cellular membrane proteins, was re-suspended in the Upper Phase Solution,
incubated on ice for 5 min, mixed with the Lower Phase Solution, and micro-centrifuged at 1000× g for
5 min. The upper phase of the solution mix was carefully collected, micro-centrifuged at 1000× g for
5 min, diluted in water, kept on ice for 5 min, and micro-centrifuged at top speed for 10 min. The pellet,
which contains plasma membrane proteins, was dissolved in 0.5% Triton X-100 in PBS.
4.7. Statistical Analyses
All values were presented as mean ± SEM. The significance of the difference between two means
was tested using Student’s t test, whereas means from multiple groups were compared using one-way
ANOVA. All statistical analyses were performed with Origin 7.0 (OriginLab, Northampton, MA, USA).
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Abbreviations
The following abbreviations are used in this manuscript:
Aha1 activator of Hsp90 ATPase homolog 1
BFA brefeldin A
CFTR cystic fibrosis transmembrane conductance regulator
Cl- chloride
DMEM Dulbecco’s modified Eagle’s medium
D-PBS Dulbecco’s phosphate buffered saline
DTT dithiothreitol
ER endoplasmic reticulum
FKBP8 FK506-binding protein 8
GAPDH glyceraldehyde 3-phosphate dehydrogenase
GST glutathione S-transferase
HEK human embryonic kidney
HOP Hsp70/Hsp90 organizing protein
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Hsc70 heat shock cognate protein 70
Hsp90β heat shock protein 90β
PBS phosphate buffered saline
PMSF phenylmethylsulfonyl fluoride
SR sarcoplasmic reticulum
TBS Tris buffered saline
TGN38 trans-Golgi network 38
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